Saroglitazar Magnesium

沙罗格列扎镁

Report date: 2026/05/13 20:02:10
NME

Base Information

Drug NameSaroglitazar Magnesium
Drug Alias Name沙格列扎Saroglitazarum赛格列扎Saroglitazar沙罗格列扎 +[10
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator activated receptor agonists
TargetsPeroxisome proliferator activated receptor
Therapy Area/IndicationsFibrosisDyslipidemiasDiabetes Mellitus, Type 2 +[11
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2013/03/05
Country/TerritoryUnited StatesPuerto RicoMexico +[6
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesZydus Cadila
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsFibrosisDiabetes Mellitus, Type 2Renal Insufficiency +[9
Inactive IndicationsDyslipidemiasLiver Cirrhosis, Biliary

Other Information

ATC CodeC10A
Related LinksWikipedia